× Industry Reports Services Press Release Contact us About us

North American Monoclonal Antibodies Market size to cross $180 Bn by 2027

 Request a sample

North American Monoclonal Antibodies Market size is projected to reach USD 180 billion by 2027, according to a latest forecast report by Graphical Research.

Increasing number of products launches coupled with rising number of monoclonal antibodies (mAbs) approval are the factors enhancing market growth. Significant growth in pipeline of mAbs and rise in research & development activities for various infectious diseases and diseases with unmet therapy are also impacting the market size. The mAbs are now being explored in wide range of infectious diseases including coronavirus, Ebola, influenza, HIV, dengue, and Zika among others.

Technological advancements have allowed researchers to expand product type such as bispecific antibodies that can bind multiple targets and mAbs type from basic naked to more complex structure. In addition, the growth in mAbs product sales is primarily due to expansion of biopharmaceuticals companies in the region, that results from increasing geriatric population and large patient pool.

The COVID-19 pandemic has positively impacted the overall market. The SARS-COV-2 monoclonal antibodies have the potential to be used for both treatment and prevention. Significant surge in the licensing of mAbs for COVID-19 treatment and prevention have stimulated the market growth. Furthermore, rising number of SARS-Cov-2 variants have also increased research and development activities.

Browse detailed statistical insights from the report, “North America Monoclonal Antibodies Market Forecast 2027 By Application (Oncology, Autoimmune Diseases, Infectious Diseases), By Type (Fully Human, Humanized, Chimeric), By End-use (Hospitals, Clinics), Research Report, Country Outlook (U.S., Canada), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share” along with the table of contents (ToC) @


The humanized monoclonal antibody segment is forecasted to expand at 13.8% CAGR during the analysis period. The humanized mAbs are one of the dominant modalities used in wide range of therapeutic applications. Factors such as its ability to efficiently manipulate their effector functions while avoiding immunogenicity are adding growth to the segment. Humanized mAbs have wide usage in therapeutic drugs for the treatment of diseases such as psoriasis, transplant rejection, infectious disease, cancer, asthma, and arthritis. Thus, wide acceptance of humanized monoclonal antibodies in various therapeutic class will augment the market growth.

The infectious disease segment will exhibit fastest growth in near term. Significant surge in COVID-19 cases and rising number of product approvals are the factors contributing to the market growth. For instance, in May 2021, the U.S. FDA announced an emergency use of mAb therapy Sotrovimab for mild-to-moderate Coronavirus infectious patients. Thus, speedy approval and growing demand for COVID-19 monoclonal antibodies will drive the segment growth.

Clinics segment was valued at USD 14 billion in 2020. Increasing usage of monoclonal antibodies in clinics for various infectious and chronic disease are the factors augmenting the segment growth. Moreover, shortage of hospital beds has shifted the preference for treatment and consultation in clinics, thereby creating product demand. In addition, technological advancements in various clinical facilities and supportive government policies will contribute to the segment growth in future.

U.S. monoclonal antibodies market is anticipated to proceed at 13.6% CAGR between 2021 to 2027. The presence of large patient pool and major industry players are the factors adding growth to market. Expansion of manufacturing capacity and increasing number of product launches will stimulate the market growth. Furthermore, speedy FDA approval and favorable government initiative to spread awareness about mAbs will also augment the demand for the market.

The market for monoclonal antibodies in North American research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2016 to 2027, for the following segments:

North America Market, By Type

  • Fully Human
  • Humanized
  • Chimeric
  • Others

North America Market, By Application

  • Oncology
  • Autoimmune diseases
  • Infectious diseases
  • Others

North America Market, By End-use

  • Hospitals
  • Clinics
  • Others

The above information has been provided for the following countries:

  • North America
    • U.S.
    • Canada